Who Should Not Take A GLP-1 Drug?

The short answer: Every FDA-approved GLP-1 drug is contraindicated for people with a personal or family history of medullary thyroid carcinoma (MTC), people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and people who had a serious allergic reaction to the drug. The labels also tell people who are pregnant, or planning to be, to stop or avoid these drugs. Beyond that, the labels flag conditions that call for caution rather than a hard no: pancreatitis, severe gastroparesis, gallbladder disease, dehydration-related kidney injury, and diabetic retinopathy.

What are the absolute contraindications on the FDA labels?

A contraindication is the strongest warning a drug label carries: the drug should not be used in that group. For the six brand-name GLP-1 drugs, section 4 of each label lists the same two items.

• A personal or family history of MTC, or a diagnosis of MEN 2. This appears on the labels for Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, and Victoza.
• A prior serious hypersensitivity reaction to the active drug (semaglutide, tirzepatide, or liraglutide) or to any ingredient in the product. The labels name anaphylaxis and angioedema as examples.

The thyroid contraindication comes from a boxed warning, the FDA's most prominent type. In rodents, these drugs cause thyroid C-cell tumors. The labels state it is unknown whether the same happens in humans, and that calcitonin tests or thyroid ultrasound are "of uncertain value" for early detection.

The Wegovy, Zepbound, Saxenda, and Victoza labels say coadministration with any other GLP-1 receptor agonist is not recommended. Taking Ozempic and Wegovy together is outside the label. If you are choosing between products, see our guide to GLP-1 medications compared.

Can you take a GLP-1 drug while pregnant or breastfeeding?

The weight-management products are the clearest. The Zepbound label says: "When pregnancy is recognized, discontinue ZEPBOUND." The Saxenda label uses the same instruction. The Wegovy label says to discontinue the drug in pregnant patients using it for weight reduction. All three note that weight loss offers no benefit during pregnancy and that animal studies showed fetal harm.

The diabetes products (Ozempic, Mounjaro, Victoza) use softer language: use during pregnancy only if the potential benefit justifies the potential risk to the fetus. That reflects the real danger of poorly controlled diabetes in pregnancy.

Timing matters. The Ozempic and Wegovy labels say to stop semaglutide at least 2 months before a planned pregnancy because of its long half-life. The American Diabetes Association's 2026 Standards of Care go further. Recommendation 15.21 states that GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists "should be discontinued prior to pregnancy, and contraception should be used while taking them."

For breastfeeding, the data are thin. The Ozempic and Victoza labels say there are no data on the drug in human milk. The Wegovy tablet label says breastfeeding is not recommended because of an absorption enhancer in the pill. The Zepbound label reports tirzepatide in breast milk was undetectable or very low, at less than 0.02% of the maternal dose. None of the labels call breastfeeding safe.

What about type 1 diabetes or a history of pancreatitis?

No GLP-1 drug is approved for type 1 diabetes. Ozempic, Mounjaro, and Victoza are indicated for type 2 diabetes only. The Wegovy label states that its use "in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated." The ADA's 2026 pharmacologic treatment chapter describes trials of liraglutide as an add-on in type 1 diabetes, with modest A1C reductions of about 0.4%, but it does not endorse routine use. A GLP-1 drug never replaces insulin in type 1 diabetes.

Pancreatitis sits in the warnings section rather than the contraindications. Every label says acute pancreatitis, including fatal hemorrhagic or necrotizing cases, has been observed with GLP-1 receptor agonists. The instruction is the same across products: if pancreatitis is suspected, stop the drug. Older versions of the Mounjaro label said the drug "has not been studied in patients with a history of pancreatitis." The current labels dropped that line, but the ADA is direct in Table 9.2: do not initiate a GLP-1 drug in someone at high risk for pancreatitis.

Which digestive, gallbladder, and kidney problems call for caution?

GLP-1 drugs slow stomach emptying, so the labels single out people whose stomach already empties slowly. Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, and Victoza all state the drug "is not recommended in patients with severe gastroparesis." The ADA repeats this: GLP-1 receptor agonists are not recommended for individuals with gastroparesis.

Gallbladder disease is a separate warning. In adults, the Wegovy label reports cholelithiasis (gallstones) in 1.6% of injection users versus 0.7% on placebo. The Saxenda label reports 2.2% versus 0.8%. The labels do not forbid use after gallbladder problems, but they tell prescribers to investigate new symptoms.

Kidney injury is tied to dehydration, not to the drug directly. Every label describes postmarketing reports of acute kidney injury, sometimes requiring dialysis, in patients whose nausea, vomiting, or diarrhea led to volume depletion. The labels advise monitoring kidney function in anyone with severe gastrointestinal reactions. For the full picture, read our complete guide to GLP-1 side effects.

Does diabetic retinopathy rule out semaglutide or tirzepatide?

It does not rule it out, but it changes the monitoring plan. In the 2-year SUSTAIN 6 cardiovascular trial, the Ozempic label reports diabetic retinopathy complications in 3.0% of semaglutide patients versus 1.8% on placebo. Among patients with a history of retinopathy at baseline, the rates were 8.2% versus 5.2%. The label attributes part of this to rapid improvement in blood sugar, a known trigger for temporary worsening of retinopathy.

The tirzepatide labels take a narrower stance. Mounjaro and Zepbound have not been studied in patients with nonproliferative retinopathy requiring acute therapy, proliferative retinopathy, or diabetic macular edema. Both labels say patients with a history of diabetic retinopathy should be monitored for progression. The ADA advises close monitoring in people at high risk, meaning older adults and those with type 2 diabetes for 10 years or more. Drug-specific detail on semaglutide lives at ozempic.md.

What about mood, surgery, and other medications?

The mood warning changed this year. On January 13, 2026, the FDA asked the makers of Saxenda, Wegovy, and Zepbound to remove the suicidal behavior and ideation warning from their labels. The agency's review included a meta-analysis of 91 placebo-controlled trials with 107,910 patients and a claims-based cohort of 2,243,138 users. It found no increased risk. This followed a January 2024 preliminary review that reached the same conclusion but could not yet rule out a small risk. The FDA still tells patients to report new or worsening depression, suicidal thoughts, or unusual mood changes. A history of depression is not a contraindication, but disclose it.

Surgery is a timing issue. Every label now warns about pulmonary aspiration during general anesthesia or deep sedation, because food may still be in the stomach. Patients should tell their care team about the drug before any procedure. Details are in GLP-1 drugs before surgery and anesthesia.

Two interactions deserve a mention. Anyone on insulin or a sulfonylurea faces a higher risk of low blood sugar when a GLP-1 drug is added, and the prescriber may need to lower those doses. The Mounjaro and Zepbound labels also say oral hormonal contraceptives may work less well because of delayed stomach emptying. They advise a non-oral or added barrier method for 4 weeks after starting and after each dose increase.

The bottom line

Three groups should not take a GLP-1 drug under any current FDA label: people with a personal or family history of medullary thyroid carcinoma, people with MEN 2, and people who had a serious allergic reaction to the drug. People who are pregnant or planning pregnancy should stop, with semaglutide needing at least 2 months of lead time. The drugs are not approved for type 1 diabetes and are not recommended in severe gastroparesis.

Everything else on the labels is a caution, not a ban. Pancreatitis history, gallbladder disease, kidney disease, diabetic retinopathy, upcoming surgery, and oral contraceptives all require a plan with a prescriber who knows your full history.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Talk with a licensed clinician about your personal and family medical history before starting, changing, or stopping any GLP-1 medication.